NCT05683379
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
Active, Not Recruiting
Not specifiedAges 0–25ObservationalREGENXBIO Inc.
~200 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:AAV8 DetectCDx
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of anti-AAV8 antibodies in patients with DMD
Measured over 90 days
Conditions
NCT05683379
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Rare Disease Research
Atlanta, Georgiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Males at least 0 to \<25 years of age
Diagnosis of DMD
Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements
Exclusion
Prior participation in a gene therapy trial OR recipient of a gene therapy drug
What this trial measures
- Prevalence of anti-AAV8 antibodies in patients with DMD90 days
* To evaluate the prevalence of AAV8 antibodies in patients with DMD * To identify participants who may be eligible for investigational gene therapy clinical trials in males with DMD